Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03709940
Other study ID # ConnectADHD
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 3, 2013
Est. completion date March 10, 2016

Study information

Verified date October 2018
Source King's College London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study investigates whether a relationship exists between pre-treatment brain characteristics and treatment response in adults with Attention Deficit Hyperactivity Disorder (ADHD).


Description:

There is a pressing need in psychiatry to offer more individualised treatments, and to improve outcomes from clinical trials. This 'individualised medicine' approach requires the development of biomarkers of treatment response.

60 adults with ADHD are recruited from the Adult ADHD Clinic at the Maudsley Hospital, London, United Kingdom.

The study is developed over three sessions, two at baseline (DAY 1 and DAY 2) and one after two months of treatment (follow-up).

The first two sessions are conceived as a single-blind non-randomised placebo-controlled cross-over experiment. The first 30 participants enrolled in the study receive a placebo tablet (ascorbic acid 50 mgs) on DAY 1 before the behavioural assessment and magnetic resonance imaging (MRI) scan. The behavioural assessment and the functional MRI measurements are repeated two days after (DAY 2), under a clinically effective dose (20 mgs) of short-acting methylphenidate (MPH).

The order of the tablets is reverted for the remaining 30 participants to balance any potential expectation and practice effect between the two conditions. Placebo and medication are over-encapsulated with the same red opaque capsules by the pharmacy team. Also, the protocol followed during the two sessions is absolutely identical in respect of timing and tests administered in order to keep the participants blind to the drug condition (medication or placebo).

After the scanning sessions, all the participants receive the same prescription of a long-acting formulation of MPH, according to the clinical guidelines adopted by the Maudsley Hospital. Treatment response is evaluated clinically and behaviourally after 2 months of treatment (follow-up). Pre-treatment brain characteristics are tested as potential predictors (biomarkers) of treatment response.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date March 10, 2016
Est. primary completion date January 15, 2015
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- males

- aged 18-45 years old

- intelligent quotient (IQ) > 70 (as measured by WASI)

- diagnosis of ADHD confirmed through clinical assessment (Adult ADHD Clinic)

- non-medicated (stimulant medication-naive or not taking stimulant medication for at least 4 weeks)

Exclusion Criteria:

- no other brain disorders other than ADHD

- no condition precluding MRI scanning (e.g., metallic implants, claustrophobia)

Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Disease
  • Hyperkinesis

Intervention

Drug:
MPH
Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.

Locations

Country Name City State
United Kingdom King's College London London

Sponsors (2)

Lead Sponsor Collaborator
King's College London Shire

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diffusion imaging-based measurements as statistically significant predictors of treatment response (i.e. of participants' performance on adult ADHD rating scale at follow-up as compared to baseline). Diffusion based measurements include specific measures of anatomical connectivity of pathways originating in the frontal lobes, such as the fronto-striatal pathways and the superior longitudinal fasciculus. According to previously published criteria, treatment response is defined as a symptomatic improvement of at least 30%, as measured by participants' performance on adult ADHD rating scale at follow-up as compared to baseline. In the month 2-3 following the last scan.
Secondary Functional connectivity measurements as statistically significant predictors of treatment response (i.e. of participants' performance on adult ADHD rating scale at follow-up as compared to baseline). Functional connectivity measurements include the strength of functional connectivity along pathways originating in the frontal lobes, such as the fronto-striatal pathways and the attentive networks. Treatment response is defined as in outcome 1. In the month 4-5 following the last scan.
Secondary Diffusion imaging-based measurements as statistically significant predictors of treatment response defined by a data-driven approach. A categorical approach (data-driven analysis using multivariate k-mean clustering) is used to define treatment response on the basis of clinical and behavioural characteristics at follow-up. Clinical characteristics include participants' performance on adult ADHD rating scale at follow-up as compared to baseline, whereas behavioural characteristics include participants' performance on the Qb test at follow-up as compared to baseline. In the month 6-7 following the last scan.
Secondary Functional connectivity measurements as statistically significant predictors of treatment response as defined by a data-driven approach. Treatment response is defined as in outcome 3. In the month 8-9 following the last scan.
See also
  Status Clinical Trial Phase
Completed NCT03260205 - Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) Phase 3
Withdrawn NCT03546400 - Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. Phase 4
Completed NCT02917109 - LearningRx Cognitive Training for ADHD N/A
Completed NCT02248948 - Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children N/A
Recruiting NCT01750307 - The Relationship of Essential Fatty Acids to Adult ADHD: The OCEAN Study (Oils and Cognitive Effects in Adult ADHD Neurodevelopment) N/A
Recruiting NCT06170996 - Internet-Assisted Behavioral Parent Training Intervention for Children With Attention Deficit Hyperactivity Disorder N/A
Completed NCT00735371 - Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Phase 3
Withdrawn NCT03580005 - A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. Phase 4
Completed NCT02578030 - Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD Phase 1
Completed NCT02574273 - Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program) N/A
Completed NCT02257216 - Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD) N/A
Recruiting NCT04943796 - A Study to Learn About the Occurrence of ADHD in Adults With Mental Conditions and Their Quality of Life
Recruiting NCT04634006 - Home-Based tDCS in Children With ADHD: A Randomized, Sham-Controlled tDCS and fNIRS Study N/A
Active, not recruiting NCT02908802 - Probiotic Supplement as Treatment for Students With ADHD N/A
Completed NCT02604407 - Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) Phase 3
Completed NCT05870605 - Drug Use Study With Intuniv® in European Countries
Terminated NCT03481959 - Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity Phase 3
Terminated NCT03638466 - Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With Attention-Deficit/Hyperactivity Disorder Phase 2
Completed NCT02795637 - Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction Phase 1
Completed NCT01533493 - Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study N/A